HUP9902769A2 - Eprosartan-dihidrát, valamint eljárás a vegyület előállítására és formálására - Google Patents

Eprosartan-dihidrát, valamint eljárás a vegyület előállítására és formálására

Info

Publication number
HUP9902769A2
HUP9902769A2 HU9902769A HUP9902769A HUP9902769A2 HU P9902769 A2 HUP9902769 A2 HU P9902769A2 HU 9902769 A HU9902769 A HU 9902769A HU P9902769 A HUP9902769 A HU P9902769A HU P9902769 A2 HUP9902769 A2 HU P9902769A2
Authority
HU
Hungary
Prior art keywords
dihydrate
formulation
production
imidazolyl
thienyl
Prior art date
Application number
HU9902769A
Other languages
English (en)
Inventor
Sarma Duddu
Nageswara R. Palepu
Gopadi M. Venkatesh
Original Assignee
Smithkline Beecham Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21765344&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP9902769(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smithkline Beecham Corp. filed Critical Smithkline Beecham Corp.
Publication of HUP9902769A2 publication Critical patent/HUP9902769A2/hu
Publication of HUP9902769A3 publication Critical patent/HUP9902769A3/hu
Publication of HU228263B1 publication Critical patent/HU228263B1/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

A találmány (E)-2-{[1H-2-bűtil-1-(4-karbőxi-benzil)-5-imidazőlil]-metilén}-3-(2-tienil)-prőpiőnsav-mőnőmetánszűlfőnát-dihidrátra, avegyületet tartalmazó gyógyszerkészítményekre, a vegyület és agyógyszerkészítmények előállítási eljárásaira, valamint az (E)-2-{[1H-2-bűtil-1-(4-karbőxi-benzil)-5-imidazőlil]-metilén}-3-(2-tienil)-prőpiőnsav-mőnőmetánszűlfőnát-dihidrátnak angiőtenzin II (AII)receptőrők blőkkőlására, valamint hipertenzió, kőngesztívszívelégtelenség és veseelégtelenség kezelésére szőlgáló alkalmazásieljárásaira vőnatkőzik. ŕ
HU9902769A 1996-03-29 1997-03-26 Eprosartan dihydrate and a process for its production and formulation HU228263B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1441496P 1996-03-29 1996-03-29
PCT/US1997/004877 WO1997036874A1 (en) 1996-03-29 1997-03-26 Eprosartan dihydrate and a process for its production and formulation

Publications (3)

Publication Number Publication Date
HUP9902769A2 true HUP9902769A2 (hu) 2000-03-28
HUP9902769A3 HUP9902769A3 (en) 2000-04-28
HU228263B1 HU228263B1 (en) 2013-02-28

Family

ID=21765344

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9902769A HU228263B1 (en) 1996-03-29 1997-03-26 Eprosartan dihydrate and a process for its production and formulation

Country Status (36)

Country Link
EP (1) EP0889880B1 (hu)
JP (1) JP4316013B2 (hu)
CN (2) CN1214682A (hu)
AP (1) AP901A (hu)
AR (1) AR006439A1 (hu)
AT (1) ATE239723T1 (hu)
AU (1) AU726694B2 (hu)
BG (1) BG64095B1 (hu)
BR (1) BR9708336A (hu)
CA (1) CA2250395C (hu)
CZ (1) CZ293345B6 (hu)
DE (1) DE69721749T2 (hu)
DK (1) DK0889880T3 (hu)
DZ (1) DZ2199A1 (hu)
EA (1) EA001958B1 (hu)
EG (1) EG23889A (hu)
ES (1) ES2198564T3 (hu)
HK (1) HK1016594A1 (hu)
HU (1) HU228263B1 (hu)
ID (1) ID16507A (hu)
IL (1) IL126319A0 (hu)
MA (1) MA24437A1 (hu)
MY (1) MY117682A (hu)
NO (2) NO311760B1 (hu)
NZ (1) NZ332008A (hu)
OA (1) OA11176A (hu)
PL (1) PL188816B1 (hu)
PT (1) PT889880E (hu)
RO (1) RO118870B1 (hu)
SK (1) SK282346B6 (hu)
TR (1) TR199801954T2 (hu)
TW (1) TW434239B (hu)
UA (1) UA49880C2 (hu)
UY (1) UY24504A1 (hu)
WO (1) WO1997036874A1 (hu)
ZA (1) ZA972686B (hu)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2294515C (en) * 1997-06-27 2007-08-28 Smithkline Beecham Corporation Eprosartan monohydrate
BR9814877A (pt) * 1997-11-17 2000-10-03 Smithkline Beecham Corp Formulações de dosagem oral de elevada carga medicamentosa de liberação imediata e modificada e processos para sua fabricação
US6558699B2 (en) * 1997-11-17 2003-05-06 Smithkline Beecham Corporation High drug load immediate and modified release oral dosage formulations and processes for their manufacture
ID25640A (id) 1998-03-04 2000-10-19 Takeda Chemical Industries Ltd Preparat pelepasan terus menerus untuk antagonistik aii, produksi dan penggunaannya
ZA991922B (en) * 1998-03-11 1999-09-13 Smithkline Beecham Corp Novel compositions of eprosartan.
PL193673B1 (pl) * 1998-07-20 2007-03-30 Smithkline Beecham Corp Bezpostaciowa sól amonowa eprosartanu,jej granulat i biologicznie ulepszony preparat oraz sposoby ich wytwarzania i zastosowanie
GB9820405D0 (en) * 1998-09-18 1998-11-11 Smithkline Beecham Plc Process
AU1157500A (en) * 1998-11-06 2000-05-29 Boehringer Ingelheim International Gmbh Medicaments based on combinations of lacidipine and telmisartan or of physiological derivatives thereof
AU1042199A (en) * 1998-11-06 2000-05-29 Boehringer Ingelheim International Gmbh Antihypertensive medicaments containing lacidipine and telmisartan
CZ301913B6 (cs) * 1999-04-28 2010-07-28 Takeda Pharmaceutical Company Limited Farmaceutický prípravek pro predcházení, lécení nebo inhibování vývoje jednoduché retinopatie nebo predproliferacní retinopatie
GB9920917D0 (en) 1999-09-03 1999-11-10 Sb Pharmco Inc Novel process
GB9920919D0 (en) 1999-09-03 1999-11-10 Sb Pharmco Inc Novel compound
KR20020089433A (ko) * 2000-04-12 2002-11-29 노파르티스 아게 유기화합물의 조합
CA2467095A1 (en) * 2001-11-23 2003-05-30 Solvay Pharmaceuticals Gmbh Hypertonia treatment during the acute phase of a cerebrovascular accident
KR100517638B1 (ko) 2002-04-08 2005-09-28 주식회사 엘지생명과학 게미플록사신 산염의 새로운 제조방법
EG24716A (en) 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
RU2004137109A (ru) * 2002-05-17 2005-10-10 Новартис АГ (CH) Комбинация блокатора рецептора ангиотензина ii и бетаблокатора для вторичной профилактики инфаркта миокарда
DE10230272A1 (de) * 2002-07-05 2004-01-22 Solvay Pharmaceuticals Gmbh AT1-Rezeptorantagonisten zur Prävention von Folgeschlaganfällen
CA2514921C (en) 2003-01-31 2013-04-30 Sankyo Company, Limited Combined use of olmesartan medoxomil and azelnidipine or amlodipine for the treatment of arteriosclerosis and hypertension
US8361507B2 (en) 2007-07-25 2013-01-29 Hetero Drugs Limited Eprosartan mesylate crystalline particles and a process for preparing pure eprosartan
WO2009084028A2 (en) * 2007-12-03 2009-07-09 Neuland Laboratories Ltd Improved process for manufacturing anhydrous (e)-3-[2-butyl-1- {(4-carboxyphenyl) methyl}-1h-imidazole-5-yl]-(thiophen-2- ylmethyl)prop-2-enoic acid methane sulfonate
CN101333216A (zh) 2008-08-03 2008-12-31 浙江华海药业股份有限公司 一种新的依普罗沙坦甲磺酸盐成盐工艺
CN113354553B (zh) * 2021-06-03 2023-09-15 北京宝诺康医药科技有限公司 一种甲氧氯普胺单盐酸盐一水合物的制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5185351A (en) * 1989-06-14 1993-02-09 Smithkline Beecham Corporation Imidazolyl-alkenoic acids useful as angiotensin II receptor antagonists
US5312828A (en) * 1989-06-14 1994-05-17 Finkelstein Joseph A Substituted imidazoles having angiotensin II receptor blocking activity
AU9137791A (en) * 1990-12-14 1992-07-08 Smithkline Beecham Corporation Imidazolyl-alkenoic acids

Also Published As

Publication number Publication date
EA001958B1 (ru) 2001-10-22
HK1016594A1 (en) 1999-11-05
NO311760B1 (no) 2002-01-21
PL329046A1 (en) 1999-03-01
MY117682A (en) 2004-07-31
EP0889880A1 (en) 1999-01-13
EA199800873A1 (ru) 1999-02-25
MA24437A1 (fr) 1998-10-01
DE69721749T2 (de) 2004-03-25
JP4316013B2 (ja) 2009-08-19
AP9700956A0 (en) 1997-04-30
ATE239723T1 (de) 2003-05-15
EP0889880B1 (en) 2003-05-07
UA49880C2 (uk) 2002-10-15
CA2250395C (en) 2005-09-06
BG102822A (en) 1999-11-30
NZ332008A (en) 1999-05-28
IL126319A0 (en) 1999-05-09
TR199801954T2 (xx) 1998-12-21
DE69721749D1 (de) 2003-06-12
CN1332167A (zh) 2002-01-23
CN1214682A (zh) 1999-04-21
WO1997036874A1 (en) 1997-10-09
JP2000508632A (ja) 2000-07-11
AU726694B2 (en) 2000-11-16
BG64095B1 (bg) 2003-12-31
PL188816B1 (pl) 2005-04-29
CA2250395A1 (en) 1997-10-09
AU2547097A (en) 1997-10-22
ZA972686B (en) 1997-09-29
TW434239B (en) 2001-05-16
HUP9902769A3 (en) 2000-04-28
SK132298A3 (en) 1999-03-12
CZ310198A3 (cs) 1999-03-17
ES2198564T3 (es) 2004-02-01
BR9708336A (pt) 1999-08-03
ID16507A (id) 1997-10-02
DZ2199A1 (fr) 2002-12-03
PT889880E (pt) 2003-09-30
DK0889880T3 (da) 2003-09-01
AP901A (en) 2000-11-23
NO984503D0 (no) 1998-09-28
AR006439A1 (es) 1999-08-25
EP0889880A4 (en) 1999-06-23
RO118870B1 (ro) 2003-12-30
HU228263B1 (en) 2013-02-28
EG23889A (en) 2007-12-12
CZ293345B6 (cs) 2004-04-14
OA11176A (en) 2003-05-13
NO2002005I1 (no) 2002-09-02
UY24504A1 (es) 1997-09-19
SK282346B6 (sk) 2002-01-07
NO984503L (no) 1998-09-28

Similar Documents

Publication Publication Date Title
HUP9902769A2 (hu) Eprosartan-dihidrát, valamint eljárás a vegyület előállítására és formálására
EA200400606A1 (ru) ИНГИБИТОРЫ ФАКТОРА Ха И ДРУГИХ СЕРИНОВЫХ ПРОТЕАЗ, ВОВЛЕЧЁННЫХ В КОАГУЛЯЦИОННЫЙ КАСКАД
MXPA04004464A (es) Compuestos de heteroarilo sustituido con azabiciclo para el tratamiento de enfermedades.
RS50140B (sr) Postupak za dobijanje perkihinina i njegova upotreba
CA2234642A1 (en) 3,4-diaryl-2-hydroxy-2,5-dihydrofurans as prodrugs to cox-2 inhibitors
MXPA03011954A (es) Nuevos derivados de acido sulfonico.
TR200201168T2 (tr) CGRP-Antagonistleri-yeni siklopropanlar içeren ilaçlar ve üretim yöntemleri.
HUP0402391A2 (hu) Telmisartan kristályos nátriumsója, eljárás előállítására és az azt tartalmazó gyógyszerkészítmények
DK0808303T3 (da) 5-(4-subst.-piperidinyl-1)-3-aryl-pentansyrederivater som tachykininreceptorantagonister
FI932552A0 (fi) Foerfarande foer framstaellning av en fast enhet doseringsform foer reglerad utloesningen
NO20004502L (no) Nye sammensetninger av eprosartan
CA2310028A1 (en) High drug load immediate and modified release oral dosage formulations and processes for their manufacture
Ashton et al. Renin inhibitors containing C-termini derived from mercaptoheterocycles
HUP0201624A2 (hu) Eprosartan arginin töltéssemlegesítő komplex, valamint eljárás az előállítására és ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
NO20010559D0 (no) Fremgangsmåte for syntese av (1H)-benzo[c]kinolizin-3-ones derivater
CA2294515A1 (en) Eprosartan monohydrate
MY118704A (en) Process for preparation of eprosartan
WO2001081298A3 (en) Cyclic carboxylic acids as integrin antagonists
NO982107D0 (no) Fremstilling av et salt av klavulansyre
ATE307809T1 (de) Neuartige pyrimidin-derivate und verfahren zu ihrer herstellung
HUP0203650A2 (hu) Heterociklusos származékok, eljárás az előállítására, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
ATE349545T1 (de) Enzymatisches verfahren zur herstellung von substituierter 2-amino-3-(2-amino-phenylsulfanyl)-propionsäure
TNSN98190A1 (fr) Derive d'indole utile en therapeutique, procede pour sa production et formulation pharmaceutique le contenant
TR200200307T2 (tr) Alfa-Kloroepoksi esterleri vasıtasıyla asit hazırlama prosesi
WO2002030876A3 (en) Cyclic carboxylic acids as integrin antagonists